GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

the recent agreement to acquire IDRx being a great example of what we want to do here. Next slide, please. Looking at GSK's launch portfolio over the next five years, we expect it to offer scale ...

Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...